Stockscreener 앱 받기
5.36
0.56%
-0.03
시간 외 거래:
5.31
-0.05
-0.93%
Valneva Se Adr 주식(VALN)의 최신 뉴스
VALN Q1 2026 Earnings: Significant EPS Miss Highlights Development‑Stage Cash BurnEstimate Dispersion - newsline.com
VLA.PA Technical Analysis | Trend, Signals & Chart Patterns | VALNEVA SE (EPA:VLA) - ChartMill
VALNEVA:Declaration of shares and voting rights - GlobeNewswire Inc.
VALN Q1 2026 Earnings: Significant EPS Miss Drives Stock DeclineEarnings Acceleration Picks - newsline.com
Valneva (VALN) Holds Steady Near Support as Traders Weigh Near-Term CatalystsMarket Cap Weight - The Legal Advocate
VLA.PA Stock Price, Quote & Chart | VALNEVA SE (EPA:VLA) - ChartMill
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Valneva SE earnings missed by $0.24, revenue fell short of estimates - Investing.com
Valneva Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Valneva SE Q1 2026 reports revenue decline, stock dips - Investing.com Nigeria
Earnings call transcript: Valneva SE Q1 2026 reports revenue decline, stock dips By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Investors to Connect - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SEVALN - PR Newswire
Valneva’s €84M Cash Injection Comes With a Bitter Pill for Shareholders - AD HOC NEWS
Valneva shares slide after US pullback on chikungunya vaccine filing - MSN
Valneva (NASDAQ:VALN) Sets New 12-Month Low After Analyst Downgrade - MarketBeat
Valneva SE Sponsored ADR (NASDAQ:VALN) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Goldman Sachs downgrades Valneva stock rating to sell on Lyme vaccine uncertainty - Investing.com
Valneva (NASDAQ:VALN) Shares Gap UpTime to Buy? - MarketBeat
Valneva's Dual Challenge: Legal Scrutiny Meets Commercial Reality - AD HOC NEWS
Guggenheim cuts Valneva stock price target to $11 on Lyme vaccine - Investing.com
Valneva SE Under Investigation for Securities Fraud - Intellectia AI
VALN stock nosedives on mixed results from Lyme disease vaccine study - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Valneva (NASDAQ:VALN) Shares Gap DownHere's Why - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Valneva Faces Mounting Legal Pressure Following Clinical Trial Setback - AD HOC NEWS
2026-04-06 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Shareholders to Learn More About the Investigation | NDAQ:VALN | Press Release - Stockhouse
Valneva's Travel Vaccines: Strategic Pivot to Emerging Markets Drives Long-Term Investor Value in Bi - AD HOC NEWS
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Declaration of shares and voting rights of Valneva SE – March 2026 - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
1.27%
1.43%
자본화:
|
볼륨(24시간):